BioSpace News Archive

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced financial results for the fourth quarter and full year ended December 31, 2022.

The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai.

ConcertAI’s TeraRecon, the advanced visualization and AI Clinical SaaS category leader, today announced a partnership to offer medical imaging AI specialist Avicenna.AI’s CINA-iPE solution detecting the presence of incidental pulmonary embolisms as part of TeraRecon’s Eureka Clinical AI solution.

IAMA Therapeutics today announced that preclinical data supporting its IAMA-6 program in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27 in Boston, Massachusetts.

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”) today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023.

Avid Bioservices, Inc. announced financial results for the third quarter and nine months ended January 31, 2023.

Koya Medical announced their selection for a poster presentation of the NILE Trial at the upcoming Academy of Managed Care Pharmacy conference being held March 21-24, 2023, in San Antonio, Texas.

Cingulate Inc. and Indegene announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301, a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder, upon approval from the U.S. Food and Drug Administration.

Protalix BioTherapeutics, Inc. announced today that it does not hold cash deposits or securities at either Silicon Valley Bank or Signature Bank, nor does it have any credit facility or other financial relationship with either institution.

ObsEva SA announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy.